Targeting T regulatory (T_reg) cells in immunotherapy-resistant cancers.

ABSTRACT: Primary or secondary (i.e., acquired) resistance is a common occurrence in cancer patients and is often associated with high numbers of T regulatory (T_reg) cells (CD4⁺CD25⁺FOXP3⁺). The approval of ipilimumab and the development of similar pharmacological agents targeting cell surface proteins on T_reg cells demonstrates that such intervention may overcome resistance in cancer patients. Hence, the clinical development and subsequent approval of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) targeting agents can serve as a prototype for similar agents. Such new agents aspire to be highly specific and have a reduced toxicity profile while increasing effector T cell function or effector T/T regulatory (T_eff/T_reg) ratio. Whi

SUBMITTER: Spiliopoulou P 

PROVIDER: S-EPMC10838381 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature